Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Pharma Seeking Hospital Partnership in Heilongjiang Province

publication date: Jan 28, 2015
Shanghai Fosun Pharma is hoping to add another facility to its growing portfolio of for-profit hospitals. Fosun signed a framework agreement with the First Hospital of Qiqihar City, the second largest city in Heilongjiang Province, to partner on building a new hospital. Fosun will supply an undisclosed amount of cash for a 53% stake in the venture; First Hospital will contribute land and buildings for the remaining 47%. In addition, the two partners will form a joint venture to purchase drugs, devices, equipment and consumables for both First Hospital and the New Hospital, with a goal of lowering procurement costs. Fosun will own 51% of this second company. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital